本周主线是资本与组织形态的加速重构,而非技术突破。海外阵营出现密集的资本动作:Anthropic 收购单人规模的药物发现初创 Mithril Medicine,Formation Bio 设立六亿美元基金延续引进外部资产再转手的模式,Flagship 将三家公司合并为 Etcelera,产业界开始用并购与合并替代自建。中国阵营的讨论重心从算法叙事转向兑现与商业模式,英矽智能、百图生科等负责人公开强调落地周期与赋能定位;融资端热度延续,元示科技、百奥几何完成新一轮,行业统计显示前九个月国内融资额已超过此前三年总和,但多位基金经理同时指出纯技术叙事正在退潮。数据与模型层面,海外以数据库更新和基准建设为主,中国以方法学论文和观点输出为主。
Abstract Although machine learning has transformed protein structure prediction of folded protein ground states with remarkable accuracy, intrinsically disordered proteins and regions (IDPs/IDRs) are defined by diverse and dynamical structural ensembles that are predicted with lo
谷歌旗下Isomorphic Labs则于5月完成21亿美元B轮融资,刷新全球AI制药单笔融资纪录;英伟达与礼来宣布五年内共同投入最高10亿美元,共建AI联合创新实验室。在中国,字节跳动于6月将AI制
链接:https://baijiahao.baidu.com/s?id=1880129202907100257&wfr=spider&for=pc
AI制药的热度,最近肉眼可见。OpenAI近日再次出手,收购了一家药物研发AI协同平台——Orchestra Bio;而在今年4月,Anthropic曾以约4亿美元收购AI生物技术公司Coefficient Bio。此外,D
链接:https://baijiahao.baidu.com/s?id=1880170863871513714&wfr=spider&for=pc
OpenAI近日再次出手,收购了一家药物研发AI协同平台——Orchestra Bio;而在今年4月,Anthropic曾以约4亿美元收购AI生物技术公司Coefficient Bio。此外,DeepMind旗下的Isomorphic Labs
链接:https://baijiahao.baidu.com/s?id=1880282898009154187&wfr=spider&for=pc
他称英矽智能是AI制药领域的“老兵”,目前已进入成熟期。 “下半场不再追求简单的技术创新,重点是商业模式的落地。”任峰表示,新生代AI制药公司多从大模型起步,仍处于接受技术、模型和人才评估的阶段。两代公司技术路线不同,关注点也存在差异。 在他看来,成熟期公司还
链接:http://www.xinhuanet.com/health/20261027/b497a9e7b072409e9a49d5a6875170b5/c.html
10月24日,第十一届医药创新与投资大会在南京举行。百图生科联合创始人兼首席执行官刘维接受采访时表示,AI制药实现破局还需要三到五年,公司坚持做行业赋能者,不直接开展药物研发。 先投
链接:http://www.xinhuanet.com/health/20261027/fdb25eb57e0546d5ac9a8068dcb7de9d/c.html
Nathan Frey has stayed busy since Anthropic acquired his biotech startup Coefficient Bio this spring. The former Genentech machine-learning scientist now leads drug discovery and development research at the tech giant. Endpoints News exclusively interviewed ...
链接:https://endpoints.news/anthropics-nathan-frey-on-biopharma-partners-ma-and-pipeline/
Abstract De novo protein binders have emerged as a powerful platform for molecular recognition, yet achieving high affinity while maintaining favorable biophysical properties remains a major challenge. Here, using the SARS-CoV-2 receptor-binding domain (RBD) as a model target, we
Formation Bio, an AI-focused biotech that acquires outside assets, develops them and then hands them off, has raised a $600 million investment found to double down on that strategy. The new fund will help it ...
链接:https://endpoints.news/formation-bio-unveils-600m-fund-tied-to-existing-model/
The AI company Anthropic has acquired a drug discovery startup called Mithril Medicine, as part of its push into the life sciences. And that's where things start to get strange. Mithril is ...
链接:https://endpoints.news/anthropic-buys-a-single-person-biotech-startup-backed-by-atlas-venture/
Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.
链接:https://www.biopharmadive.com/news/flagship-etcelera-etiome-empress-cellarity-launch/872947/
After Endpoints News’ AI event in New York in October, I had dinner with some of our guests. Over a few glasses of wine, we started talking about some out-there ideas they ...
链接:https://endpoints.news/post-hoc-live-is-biotechs-future-full-of-zero-and-one-employee-startups/
| 维度 | 条数 | 中国 | 美及海外 | 代表事件 |
|---|---|---|---|---|
| 3.1 技术前沿与研发 | 42 | 4 | 38 | IDPForge: deep learning …;OpenAntigens: a structur…;Design Trade-Offs betwee… |
| 3.2 公司与生态 | 10 | 4 | 6 | Anthropic's Nathan Frey …;AI制药进入下半场 英矽智能任峰谈落地与兑现;百图生科刘维:AI制药未来三到五年有望迎来破局 |
| 3.3 投融资 | 10 | 6 | 4 | 科技巨头竞相入局,AI制药谁将笑到终局?;AI制药走到哪一步了?多位基金经理把脉;元示科技完成近亿元融资!第二代AI制药/虚拟细胞… |
| 3.4 管线与临床 | 3 | 0 | 3 | 基于药效团虚拟筛选发现EphA2拮抗剂并完成重合…;Concurrent cognitive, be…;计算重定位筛选FDA已批药物靶向CDK2 |
| 3.5 合作与交易 | 3 | 3 | 0 | 「红包」AI制药升温,创新药会迎来“科技溢价”吗…;长城基金梁福睿:重点关注AI制药产业价值分配格局;谁能成为中国AI制药之王? |
| 3.6 政策与监管 | 0 | 0 | 0 | — |
| 3.7 风险与冷静信号(关键词粗筛) | 2 | 0 | 2 | BitBIRCH实现活性悬崖高效识别与规…(命中:风险);GENESIS模型单细胞扰动预测逼近实验…(命中:可重复性) |
data/ai_pharma.db 的 news 表,按发布时间自然周(周一~周日)聚合,经 AI 制药严格预筛(AI 是核心驱动力)后本周保留 68 条。companies.region_2way,仍判不出默认美国及海外;非严谨国别统计,反映的是信源与企业阵营。python tools/make_weekly.py 2026-W44 --apply。